MCID: CHR064
MIFTS: 34

Chronic Monocytic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Chronic Monocytic Leukemia

MalaCards integrated aliases for Chronic Monocytic Leukemia:

Name: Chronic Monocytic Leukemia 12 15
Leukemia, Monocytic, Chronic 71
Leukemia, Myeloid 43

Classifications:



External Ids:

Disease Ontology 12 DOID:8593
ICD9CM 34 206.1
MeSH 43 D007951
NCIt 49 C34774
ICD10 32 C93.1
UMLS 71 C0023466

Summaries for Chronic Monocytic Leukemia

MalaCards based summary : Chronic Monocytic Leukemia, also known as leukemia, monocytic, chronic, is related to leukemia, acute myeloid and atypical chronic myeloid leukemia. An important gene associated with Chronic Monocytic Leukemia is ITGAD (Integrin Subunit Alpha D), and among its related pathways/superpathways is Phagocytosis of Microbes. The drugs Histamine and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Chronic Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Chronic Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 11.8
2 atypical chronic myeloid leukemia 11.5
3 monocytic leukemia 10.5
4 leukemia 10.5
5 myeloid sarcoma 10.3
6 lymphocytic leukemia 10.3
7 leukemia, acute lymphoblastic 10.3
8 sarcoma 10.2
9 spindle cell sarcoma 10.2
10 myelodysplastic syndrome 10.1
11 acute promyelocytic leukemia 10.1
12 childhood acute lymphocytic leukemia 10.0
13 chronic myelomonocytic leukemia 10.0
14 acute leukemia 10.0
15 histiocytosis 10.0
16 malignant histiocytosis 10.0
17 splenomegaly 10.0
18 leukemia, chronic lymphocytic 10.0
19 graft-versus-host disease 9.9
20 thrombocytopenia 9.9
21 myeloproliferative neoplasm 9.9
22 erythroleukemia, familial 9.8
23 leukemia, chronic myeloid 9.8
24 hairy cell leukemia 9.8
25 myeloid leukemia 9.8
26 leukemia, acute lymphoblastic 3 9.7
27 cholangiocarcinoma 9.7
28 aggressive nk-cell leukemia 9.7
29 prolymphocytic leukemia 9.7
30 hydronephrosis 9.7
31 subleukemic leukemia 9.7
32 melanoma 9.7
33 essential thrombocythemia 9.7
34 systemic mastocytosis 9.7
35 mastocytosis 9.7
36 intrahepatic cholangiocarcinoma 9.7
37 appendicitis 9.7
38 mast-cell leukemia 9.7
39 acute leukemia of ambiguous lineage 9.7
40 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.7
41 chronic graft versus host disease 9.7
42 core binding factor acute myeloid leukemia 9.7
43 precursor t-cell acute lymphoblastic leukemia 9.7

Graphical network of the top 20 diseases related to Chronic Monocytic Leukemia:



Diseases related to Chronic Monocytic Leukemia

Symptoms & Phenotypes for Chronic Monocytic Leukemia

GenomeRNAi Phenotypes related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.17 ITGAD
2 Decreased viability GR00381-A-1 9.17 ITGAD LGALS1
3 Decreased viability GR00381-A-2 9.17 LGALS1
4 Decreased viability GR00381-A-3 9.17 ITGAD LGALS1
5 Decreased viability GR00402-S-2 9.17 LGALS1

Drugs & Therapeutics for Chronic Monocytic Leukemia

Drugs for Chronic Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 548)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
3
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
6
Lenalidomide Approved Phase 4 191732-72-6 216326
7 Molgramostim Investigational Phase 4 99283-10-0
8
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
9 Hormones Phase 4
10 Hormone Antagonists Phase 4
11 Gemtuzumab Phase 4
12
Histamine Phosphate Phase 4 51-74-1 65513
13 Angiogenesis Inhibitors Phase 4
14
Idarubicin Approved Phase 3 58957-92-9 42890
15
Iron Approved, Experimental Phase 2, Phase 3 7439-89-6, 15438-31-0 23925 27284
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
18
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
19
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
21
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
22
Ofloxacin Approved Phase 3 82419-36-1 4583
23 Orange Approved Phase 2, Phase 3
24
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
25
Enalaprilat Approved Phase 3 76420-72-9 6917719
26
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
27
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
28
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
29
Mercaptopurine Approved Phase 3 50-44-2 667490
30
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
31
Lomustine Approved, Investigational Phase 2, Phase 3 13010-47-4 3950
32
Thioguanine Approved Phase 3 154-42-7 2723601
33
Atorvastatin Approved Phase 3 134523-00-5 60823
34
Lorazepam Approved Phase 3 846-49-1 3958
35
Captopril Approved Phase 3 62571-86-2 44093
36
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
37
Etoposide Approved Phase 3 33419-42-0 36462
38
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
39
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
40
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
41
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
42
leucovorin Approved Phase 3 58-05-9 6006 143
43
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
44
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
45
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
46
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
47
midostaurin Approved, Investigational Phase 2, Phase 3 120685-11-2 104937 9829523
48
nivolumab Approved Phase 2, Phase 3 946414-94-4
49
Coal tar Approved Phase 2, Phase 3 8007-45-2
50
Melphalan Approved Phase 3 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 2336)
# Name Status NCT ID Phase Drugs
1 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
2 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
3 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
4 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
6 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy Unknown status NCT01243489 Phase 4
7 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
8 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
9 A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML) Completed NCT00304447 Phase 4 Mylotarg
10 Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
11 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
12 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
13 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
14 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
15 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML Completed NCT00171899 Phase 4 imatinib mesylate
16 Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
17 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
18 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group. Completed NCT00180115 Phase 4 Cytarabine Dosage
19 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
20 Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy Completed NCT01819792 Phase 4
21 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
22 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
23 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib
24 A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
25 A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Completed NCT01227577 Phase 4 Nilotinib
26 AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
27 Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
28 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
29 An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
30 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
31 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
32 A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase Completed NCT03332511 Phase 4 Nilotinib
33 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
34 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
35 The Feasibility of Safely Managing Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment Recruiting NCT03988205 Phase 4 CPX-351
36 A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID Recruiting NCT02546674 Phase 4 Nilotinib
37 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415 Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
38 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
39 Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis Active, not recruiting NCT02875743 Phase 4 Posaconazole
40 A PHASE 4 SAFETY AND EFFICACY STUDY OF BOSUTINIB (BOSULIF (REGISTERED)) IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA PREVIOUSLY TREATED WITH ONE OR MORE TYROSINE KINASE INHIBITORS Active, not recruiting NCT02228382 Phase 4 Bosutinib
41 A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
42 Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic‐Phase Chronic Myeloid Leukemia (CML-CP) Not yet recruiting NCT04155411 Phase 4 Dasatinib
43 A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
44 PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5 Terminated NCT01198054 Phase 4 Lenalidomide
45 A Phase IV Study to Evaluate Efficacy and Safety of Imatinib(Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Terminated NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
46 Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib. Terminated NCT00461929 Phase 4
47 Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) Unknown status NCT01246752 Phase 3 Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
48 HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Unknown status NCT01484171 Phase 3 idarubicin
49 Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy Unknown status NCT00297570 Phase 3 Pegylated Interferon and Imatinib
50 Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study Unknown status NCT02059720 Phase 3

Search NIH Clinical Center for Chronic Monocytic Leukemia

Cochrane evidence based reviews: leukemia, myeloid

Genetic Tests for Chronic Monocytic Leukemia

Anatomical Context for Chronic Monocytic Leukemia

MalaCards organs/tissues related to Chronic Monocytic Leukemia:

40
Myeloid, T Cells, Bone, Bone Marrow, Monocytes, Nk Cells, Testes

Publications for Chronic Monocytic Leukemia

Articles related to Chronic Monocytic Leukemia:

(show top 50) (show all 88)
# Title Authors PMID Year
1
Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy. 61
31567386 2019
2
Effect of Chronic Hematologic Malignancies on In-Hospital Outcomes of Patients With ST-Segment Elevation Myocardial Infarction. 61
31196560 2019
3
Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). 61
31263893 2019
4
Immunotherapy- (Blinatumomab-) Related Lineage Switch of KMT2A/AFF1 Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia. 61
31885955 2019
5
Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia. 61
29321428 2018
6
Air pollution from industrial waste gas emissions is associated with cancer incidences in Shanghai, China. 61
29484620 2018
7
Mandible exosomal ssc-mir-133b regulates tooth development in miniature swine via endogenous apoptosis. 61
30210900 2018
8
T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation. 61
28551327 2017
9
Risk for Health Care-Associated Bloodstream Infections in Pediatric Oncology Patients With Various Malignancies. 61
28038498 2017
10
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). 61
26834952 2016
11
A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. 61
26070419 2015
12
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. 61
26304895 2015
13
Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias. 61
25728710 2015
14
Extensive placental choriovascular infiltration by maturing myeloid cells in down syndrome-associated transient abnormal myelopoiesis. 61
25587735 2015
15
Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations. 61
25619630 2015
16
Interpretation of personal genome sequencing data in terms of disease ranks based on mutual information. 61
26045178 2015
17
[Pulmonary function of children with acute leukemia in maintenance phase of chemotherapy]. 61
25510995 2014
18
A model approach to calculate cancer prevalence from 5 years survival data for selected cancer sites in India--part II. 61
25081685 2014
19
Proteome changes induced by c-myb silencing in human chronic myeloid leukemia cells suggest molecular mechanisms and putative biomarkers of hematopoietic malignancies. 61
24220303 2014
20
Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia. 61
23995854 2013
21
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. 61
23528871 2013
22
The emerging roles of Notch signaling in leukemia and stem cells. 61
24252593 2013
23
Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;). 61
23806379 2013
24
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome. 61
23049441 2012
25
Stem cell therapy in treatment of different diseases. 61
22359076 2012
26
Current views on the role of Notch signaling and the pathogenesis of human leukemia. 61
22128846 2011
27
Chemotherapeutic treatment for leukemia in a bearded dragon (Pogona vitticeps). 61
22946414 2011
28
BCR-ABL translocation in a dog with chronic monocytic leukemia. 61
21143615 2011
29
Identification of new markers discriminating between myeloid and lymphoid acute leukemia. 61
20670477 2010
30
Possible involvement of RasGRP4 in leukemogenesis. 61
19350351 2009
31
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. 61
16885047 2006
32
Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood. 61
16569592 2006
33
Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations. 61
16357944 2006
34
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. 61
15837754 2005
35
Candidal prosthetic hip infection in a patient with previous candidal septic arthritis. 61
14973873 2004
36
A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia. 61
12792926 2003
37
Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. 61
12032870 2002
38
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. 61
11001891 2000
39
Dysregulation of lymphocyte proliferation by chromosomal translocations and sequential genetic changes. 61
10797481 2000
40
Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. 61
10468608 1999
41
Pediatric tumors in north west Pakistan and Afghan refugees. 61
9185211 1997
42
11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone. 61
8948668 1996
43
Biological characterization and molecular cloning of murine C-type retroviruses derived from the TSZ complex from mainland China. 61
7571406 1995
44
[Effect of media conditioned with bone marrow fibroblasts on proliferation of leukemic blast cell lines]. 61
7875517 1994
45
[The morphofunctional characteristics of the mononuclear phagocytes in the concentrated venous blood leukocytes of patients with histiocytosis]. 61
7985129 1994
46
Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis. 61
8412328 1993
47
Interleukin 1 augments the expression of the interleukin 2 receptor alpha-chain in interleukin 6-stimulated myeloid cells by a transcriptional and posttranscriptional mechanism. 61
1426100 1992
48
Inhibition of specific pathways of myeloid cell differentiation by an activated Hox-2.4 homeobox gene. 61
1359901 1992
49
A switch toward demethylation is associated with the expression of myeloperoxidase in acute myeloblastic and promyelocytic leukemias. 61
1327288 1992
50
[Effectiveness of etoposide on reactive histiocytosis and refractory state to platelet transfusion during therapy of leukemia: case report]. 61
1942543 1991

Variations for Chronic Monocytic Leukemia

Expression for Chronic Monocytic Leukemia

Search GEO for disease gene expression data for Chronic Monocytic Leukemia.

Pathways for Chronic Monocytic Leukemia

Pathways related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.55 ITGAD C3

GO Terms for Chronic Monocytic Leukemia

Cellular components related to Chronic Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 8.8 LGALS1 ITGAD C3

Sources for Chronic Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....